Introduction {#S0001}
============

Mycosis fungoides (MF) represents the most common type of primary cutaneous lymphomas deriving from mature CD4-positive T cells (CTCL). Clinically, MF is characterized by indolent course and restriction to the skin, showing a slow evolution from macules and plaques to tumors. However, in some patients a rapid progression with metastases to lymph nodes and internal organs can be seen. Over the last decades, MF etiopathogenesis has been widely explored in depth, but still the exact mechanisms of initialization and development of this lymphoma have not been elucidated \[[@CIT0001]\].

Chemokines are a superfamily of small, 8- to 12-kDa peptides that function as chemoattractant cytokines. They mediate a number of cellular functions including activation, survival, growth, differentiation, and trafficking and exert their action by binding to surface, 7-transmembrane domain, G-protein coupled receptors on the target cells.

CXCL12 (C-X-C motif ligand 12), earlier termed stromal-derived factor-1 (SDF-1) is an α-chemokine expressed on multiple cell types, including endothelial and stromal cells, in different organs. Its receptor, CXCR4, has been documented to be expressed on most hematopoietic cell types, including CD34+ progenitor cells, CD4+ T cells, B cells, neutrophils and dendritic cells. Additionally, the expression of CXCR4 has been found on multiple solid tumors as well as hematological malignancies. Growing evidence has accumulated that the CXCL12/CXCR4 axis plays an important role in multiple processes such as stem cell mobilization, migration and homing, inflammation, infection and immunoregulation. The mechanisms employing the CXCR4/CXCL12 axis have been also implicated in tumor development, growth and metastasis \[[@CIT0002]\].

Aim {#S0002}
===

The aim of the study was to analyze the expression pattern and intensity level of CXCR4 and CXCL12 in the primary cutaneous lymphoma tissues and to compare with the expression of well-known markers of tumor progression (AgNORs, Ki-67, CD34).

Material and methods {#S0003}
====================

The material for the immunohistochemical analysis consisted of 56 archival tissue samples from the patients with histologically-proven mycosis fungoides fixed in 10% buffered formalin solution and embedded in paraffin blocks. The diagnosis and staging of the disease was assessed according to the WHO/EORTC classification and revised ISCL/EORTC classification and staging \[[@CIT0003], [@CIT0004]\]. The control group consisted of 20 healthy volunteers surgically treated in our department for cosmetic reasons.

The immuno-pathomorphological analysis of CXCR4 and CXCL12 expression {#S20004}
---------------------------------------------------------------------

The 5 µm thick slices were prepared from the paraffin blocks containing fixed tissue, then dewaxed in xylene and placed on basic slides Super Frost Plus (Menzel GmbH & Co KG, Germany). Separate slides for the assessment of the tested markers CXCR4 and CXCL12 were performed from each block. Following commercial primary antibodies against studied proteins were used for the immunohistochemical staining: CXCR4: Monoclonal Anti-human CXCR4 (fusin) Antibody; Clone: 44716; Ig class: IgG2B; Catalog Number: MAB 172; R&D SYSTEMS; dilution 1: 120;CXCL12: Monoclonal Anti-human/mouse CXCL12/SDF-1 Antibody; Clone: 79018; Ig class; mouse IgG1; Catalog Number: MAB 350; R&D SYSTEMS USA; dilution 1: 60.

The immunohistochemical procedure was performed as follows: Before the incubation with the primary antibody the antigens were exposed by boiling and incubation in 0.01 M sodium citrate buffer (pH 6.0). The activity of endogenous peroxidase was blocked with a blocking agent (Peroxidase-blocking Reagent, S2001, DAKO, Denmark) and rinsed in distilled water and phosphate-buffered saline (PBS) solution. Nonspecific immunoglobulin binding sites were blocked with the normal serum diluted with PBS, 0.1% bovine serum albumin (BSA) and 0.1% sodium azide. Then, samples were incubated with the primary antibody (standard dilution, recommended by the manufacturer with Antibody Diluent, Background Reducing (S3022, DAKO, Denmark)). Next, the biotinylated antibody was added to the samples, which were incubated at room temperature for 20 min and again rinsed in PBS. Streptavidin-biotinylated peroxidase complex (Universal LSAB^®^+Kits HRP, Rabbit/Mouse/Goat, (K 0690, DAKO, Denmark)) was added, incubated and rinsed. After staining with DAB, samples were rinsed in distilled water. Nuclei were stained with hematoxylin. Finally, the slides were dehydrated with alcoholic series and xylene and closed in DPX. Positive and negative controls were done for every staining procedure. The results of immunohistochemical staining was analyzed on the basis of the system of immunocytochemical reaction assessment using an IRS immunocytochemistry (Immunoreactive score) by Remmel own modification ([Table 1](#T0001){ref-type="table"}) \[[@CIT0005]\].

###### 

IRS Assessment scale according to Remmel (own modification) \[[@CIT0005]\]

  Percentage of cells showing reaction (%)   Points   Intensity of reaction (I)   Points
  ------------------------------------------ -------- --------------------------- --------
  Lack of the cells exhibiting reaction      0        No reaction                 0
  1--25% of positive cells                   1        Weak color reaction         1
  26--50% of positive cells                  2        Moderate color reaction     2
  51--75% of positive cells                  3        Intense color reaction      3
  76--100% of positive cells                 4                                    

According to this scale two expression categories are evaluated separately: 1) percentage of cells showing a positive staining -- from 0 to 4 points (% -- percentage) ([Table 1](#T0001){ref-type="table"}), 2) degree of color reaction -- from 0 to 3 points (I -- intensity of the reaction).

The final scoring is a result of multiplication of % and I (from 0 to 12 points) and is defined as the ratio of IRS -- RIRS.

Additionally, topography of the protein expression in lymphoma infiltration was evaluated as two categories: 1) superficial -- the dominant expression pattern in the superficial infiltrate (within the epidermis or close to the epidermis), 2) deep -- the dominant expression in the deep infiltrate (in the deeper layers of the skin).

Immunohistochemical analysis of CD34, AgNORs, and Ki-67 expression {#S20005}
------------------------------------------------------------------

The following primary antibodies were used for the detection of CD34 and Ki-67: Monoclonal Mouse Anti-human CD34, clone: Class II, QBEnd 10 (DAKO, Catalog Number N1632) and Monoclonal Mouse Anti-human Ki-67, clone: MIB-1, (DAKO catalog number N1633) were used. The exact staining procedure was described in detail elsewhere \[[@CIT0006], [@CIT0007]\].

To visualize proteins NORs, the preparations were stained according to Ploton modified by Ofner \[[@CIT0008]\]. The whole procedure was described previously \[[@CIT0006]\].

Statistical analysis {#S20006}
--------------------

Statistical analysis was performed using Statistica^®^ 9.0 software (Statsoft, Krakow, Poland). Frequencies, mean, median, minimal and maximal values were calculated, where appropriate. Students *t* test, Mann-Whitney *U* test, χ^2^ test and Spearman rank correlation test were used for statistical analysis. Values of *p* less than 0.05 were considered significant.

Results {#S0007}
=======

Expression of CXCL12 and CXCR4 {#S20008}
------------------------------

The comparison of the CXCL12 and CXCR4 expression in biopsies of MF and healthy skin is demonstrated in [Table 2](#T0002){ref-type="table"}. Both, CXCL12 and CXCR4 were expressed in more cells of lymphoma specimens than in cells of the control skin ([Figure 1](#F0001){ref-type="fig"}). Similarly, lesional skin of MF showed significantly higher immunoreactivity of CXCL12 and CXCR4 than healthy skin. The immunoreactivity score (IRS) for CXCL12 and CXCR4 was significantly higher (*p* \< 0.001, *p* \< 0.001) in mycosis fungoides (6.3 ±2.8 scores and 7.1 ±3.2 scores, respectively) than in control biopsies (1.4 ±0.8 scores and 2.2 ±1.0 scores, respectively) ([Table 2](#T0002){ref-type="table"}).

![The expression of CXCR4 in mycosis fungoides (magnification 200×)](PDIA-32-24284-g001){#F0001}

###### 

Expression of CXCL12 and CXCR4 in mycosis fungoides (MF) and healthy skin (IRS -- immunoreactive score)

  Variable                        CXCL12       CXCR4                     
  ------------------------------- ------------ ------------ ------------ ------------
  Percentage of positive cells:                                          
  0--10% (1)                      2 (3.6%)     12 (60.0%)   4 (7.1%)     4 (20.0%)
  11--50% (2)                     27 (48.2%)   7 (35.0%)    16 (28.6%)   15 (75.0%)
  51--80% (3)                     21 (37.5%)   0 (0%)       21 (37.5%)   1 (5%)
  \> 80% (4)                      6 (10.7%)    1 (5.0%)     15 (26.8%)   0 (0%)
                                                                         
  \< 0.001                        \< 0.001                               
                                                                         
  Staining intensity:                                                    
  Low (1)                         2 (3.6%)     13 (65%)     2 (3.6%)     16 (80%)
  Intermediate (2)                29 (51.8%)   7 (35%)      30 (53.6%)   4 (20%)
  High (3)                        25 (44.6%)   0 (0%)       24 (42.9%)   0 (0%)
                                                                         
  \< 0.001                        \< 0.001                               
                                                                         
  IRS, mean ± SD                  6.3 ±2.8     1.4 ±0.8     7.1 ±3.2     2.2 ±1.0
                                                                         
  \< 0.001                        \< 0.001                               
                                                                         
  Staining location:                                                     
  Superficial                     23 (41.1%)   6 (30%)      25 (44.6%)   16 (80%)
  Deep                            5 (8.9%)     0 (0%)       5 (8.9%)     0 (0%)
  Both                            28 (50%)     1 (5%)       26 (46.4%)   4 (20%)
  None                            0 (0)        13 (65%)     --           --
                                                                         
  \< 0.001                        0.02                                   

Relevance of CXCL12 and CXCR4 in MF {#S20009}
-----------------------------------

To establish the importance of CXCL12 and CXCR4 for the prognosis of mycosis fungoides we have compared them with the well-known markers of tumor progression like Ki67, CD34 and AgNORs ([Figures 2](#F0002){ref-type="fig"}, [3](#F0003){ref-type="fig"}). We did not observe any significant correlations between IRS of CXCL12 and CXCR4 and the expression of analyzed proliferation and angiogenesis markers ([Table 3](#T0003){ref-type="table"}). On the other hand, the expression of all three proliferation parameters significantly correlated between themselves ([Table 3](#T0003){ref-type="table"}). The age and gender of included patients did not significantly influence the expression of any of the studied parameters (data not shown).

![The expression of CD34 in mycosis fungoides tissue (magnification 200×)](PDIA-32-24284-g002){#F0002}

![The expression of Ki-67 in mycosis fungoides (magnification 400×)](PDIA-32-24284-g003){#F0003}

###### 

Correlations between the expression of CXCL12, CXCR4 and proliferation markers (ρ -- Spearman correlation coefficient) in MF

                   Ki67                     MVD                      AgNORs                   CXCL12 IRS               CXCR4 IRS
  ---------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------
  **Ki67**         X                        ρ = 0.68, *p* \< 0.001   ρ = 0.79, *p* \< 0.001   ρ = 0.25, *p* = 0.06     ρ = 0.05, *p* = 0.72
  **CD34**         ρ = 0.68, *p* \< 0.001   X                        ρ = 0.8, *p* \< 0.001    ρ = 0.18, *p* = 0.2      ρ = --0.02, *p* = 0.9
  **AgNORs**       ρ = 0.79, *p* \< 0.001   ρ = 0.8, *p* \< 0.001    X                        ρ = 0.23, *p* = 0.1      ρ = 0.04, *p* = 0.75
  **CXCL12 IRS**   ρ = 0.25, *p* = 0.06     ρ = 0.18, *p* = 0.2      ρ = 0.23, *p* = 0.1      X                        ρ = --0.04, *p* = 0.76
  **CXCR4 IRS**    ρ = 0.05, *p* = 0.72     ρ = --0.02, *p* = 0.9    ρ = 0.04, *p* = 0.75     ρ = --0.04, *p* = 0.76   X

When comparing the expression of Ki67, CD34, AgNORs, CXCL12 and CXCR4 with the disease status we observed that parameters of cell proliferation and angiogenesis had a significantly higher expression in more advanced stages of MF and were connected with shorter survival, whereas the expression of CXCL12 and CXCR4 did not significantly correlate with the disease course ([Table 4](#T0004){ref-type="table"}). We also did not find any significant relationships between the localization of CXCL12 and CXCR4 staining in the skin and the disease stage and patient status ([Table 4](#T0004){ref-type="table"}).

###### 

Comparison of the expression of Ki67, CD34, AgNORs, CXCL12, CXCR4 with the disease course and prognosis

  Variable               Ki67(% of cells)   CD34(microvessel density/mm^3^)   AgNORs(number)   CXCL12 IRS(scores)   CXCL12 IRS(scores)
  ---------------------- ------------------ --------------------------------- ---------------- -------------------- --------------------
  MF stage:                                                                                                         
   Early (IA--IIA)       9.4 ±9.8           121.6 ±11.4                       1.7 ±0.7         5.1 ±1.8             7.3 ±3.2
   Advanced (IIB--IVB)   20.5 ±10.3         138.2 ±20.9                       3.6 ±1.2         6.7 ±2.9             7.0 ±3.3
                         *p* \< 0.001       *p* \< 0.01                       *p* \< 0.001     *p* = 0.07           *p* = 0.81
                                                                                                                    
  Metastases:                                                                                                       
   No                    13.9 ±8.2          126.9 ±16.9                       2.6 ±1.1         6.0 ±2.7             7.2 ±3.2
   Yes                   27.4 ±12.3         151.7 ±17.1                       4.3 ±1.2         6.9 ±3.0             6.9 ±3.5
                         *p* \< 0.001       *p* \< 0.001                      *p* \< 0.001     *p* = 0.32           *p* = 0.74
                                                                                                                    
  Patient status:                                                                                                   
   Alive                 16.4 ±11.4         130.7 ±19.4                       2.9 ±1.3         4.7 ±3.3             5.6 ±3.6
   Dead                  22.9 ±9.4          146.2 ±19.3                       4.0 ±1.3         6.5 ±2.2             6.9 ±3.2
                         *p* = 0.07         *p* = 0.02                        *p* = 0.01       *p* = 0.08           *p* = 0.74

Discussion {#S0010}
==========

The expression of CXCR4 has been observed in various tumor types, including solid tumors as well as hematological malignancies. This receptor has been shown to be employed in various processes such as chemotaxis, invasion, angiogenesis and proliferation.

It has been postulated that the CXCR4/CXCL12 axis plays an important role in regulation of metastasis processes, similarly to the physiological processes of the retention/homing of hematopoietic stem cells into the bone marrow microenvironment, by trafficking CXCR4 positive malignant cells to the tissues secreting CXCL12 \[[@CIT0009]\]. The mechanism of CXCR4-CXCL12-induced metastases to the bone marrow was suggested in lung cancer \[[@CIT0010]\]. The high CXCR4 expression on melanoma malignum cells was reported by other authors who found a strong correlation between CXCR4 expression and unfavorable prognosis and shorter median disease-free and overall survival \[[@CIT0011]\]. The other reports documented the association between the overexpression of CXCR4 on malignant cells with poor overall survival in patients with breast and ovarian cancer \[[@CIT0012], [@CIT0013]\]. Similar processes were also reported in hematological malignancies. In acute lymphoblastic leukemia (ALL) it has been documented *in vivo* that CXCR4 expression plays a key role in the engraftment of ALL cells in the bone marrow microenvironment \[[@CIT0014]\]. Moreover, CXCR4 expression and its interaction with adhesion molecules are necessary for the homing of malignant cells to the bone marrow and their resistance to cytotoxic therapies in acute myelogenous leukemia and it has been found to be a negative prognostic factor \[[@CIT0015], [@CIT0016]\]. It has been postulated that in B- and T-cell non-Hodgkin lymphomas, the expression of CXCR4 on the malignant cells plays a role in lymphoma cell trafficking and homing. Skin homing of malignant lymphocytes is a hallmark of MF and Sezary syndrome (SS -- aggressive variant of CTCL) \[[@CIT0017]\]. This process is based on an interaction between CXCR4 expressed on lymphocytes and CXCL12 expressed on the fibroblasts and stromal cells in the dermis and may be enhanced by another characteristic feature of MF/SS, namely, loss of the CD26 surface antigen. Physiologically, CD26 cleaves and inactivates CXCL12 and its down-regulation increases CXCL12-dependent chemotaxis of SS cell lines \[[@CIT0018]\]. The CXCL12 expression in the tumor microenvironment provides stimulatory signals for B-cells and activated T cells in chronic leukemia \[[@CIT0019]\]. Similar phenomena may also occur in CTCL. High expression and immunoreactivity of CXCR4 and CXCL12 found by our group in MF further supports an important role of this axis in the development of this malignancy.

Uncontrolled cell proliferation is a characteristic feature of the tumor growth. Previously, we assessed the cell proliferation rate by measuring Ki-67 and AgNORs expression in MF and parapsoriasis en plaque and we found an increased expression of these biomarkers in advanced MF as compared to early MF and parapsoriasis \[[@CIT0006]\]. Taking into consideration numerous reports suggesting that the CXCR4/CXCL12 axis is involved in tumor growth promotion, in the current study we have compared the expression of proliferation markers with the expression of CXCR4 and CXCL12. Interestingly, the expression of CXCR4 and CXCL12 did not correlate with tumor progression biomarkers expression as well as did not influence the patient outcome suggesting separate mechanisms employed in both processes.

There is also growing evidence of the association between the CXCR4/CXCL12 axis and angiogenesis in tumor development by the up-regulation of the VEGF and VEGFR, one of the most potent proangiogenic factors and its receptor \[[@CIT0020]\]. Several reports linked the increased microvessel density (MVD) with a high expression of CXCR4 and CXCL12 and tumor progression in myelodysplastic syndrome and lung cancer \[[@CIT0021]--[@CIT0023]\]. Increased angiogenesis measured by MVD in cutaneous lymphomas was reported by our group elsewhere \[[@CIT0007]\], however, in view of the presented data we compared MVD measured by CD34 staining to the CXCR4/CXCL12 expression. Both MVD and CXCR4/CXCL12 expressions were increased in the lymphoma group, but there was no correlation between them, which again may suggest different mechanisms of both processes: skin homing and angiogenesis. Recently, another receptor -- CXCR7, which also binds CXCL12, was found to stimulate angiogenesis *in vitro* and *in vivo* in the rat mammary adenocarcinoma cell line MTLn3, whereas CXCR4 enhanced tumor invasiveness \[[@CIT0024]\].

Conclusions {#S0011}
===========

There is growing evidence that chemokines and their receptors play an important role in pathogenesis of MF. Our study seems to confirm by the close relationship between the expression of CXCR4/CXCL12 axis and the MF development. Several anti-CXCL12 and CXCR4 agents, including the anti-CXCR4 drug AMD3100 (plerixafor), the CXCL12 analog CTCE-9908, the anti-CXCL12 aptamer Nox-A12, have been tested with promising effects in preclinical and clinical studies as an adjunctive antitumor therapy. The CXCR4/CXCL12 axis seems to be an interesting potential target for future strategies of new drug development, giving hope for more efficacious therapies for solid tumors and hematological malignancies, including MF.
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